Skip Nav Destination
Issues
1 October 2000
ISSN 1078-0432
EISSN 1557-3265
Editorial
Minireview
Advances in Brief
Clinical Trials
A Phase I Radioimmunotherapy Trial Evaluating 90Yttrium-labeled Anti-Carcinoembryonic Antigen (CEA) Chimeric T84.66 in Patients with Metastatic CEA-producing Malignancies1
Jeffrey Y. C. Wong; David Z. Chu; Dave M. Yamauchi; Lawrence E. Williams; An Liu; Sharon Wilczynski; Anna M. Wu; John E. Shively; James H. Doroshow; Andrew A. Raubitschek
Chronic Daily Low Dose of 4-Methyl-5-(2-pyrazinyl)-1,2-dithiole-3-thione (Oltipraz) in Patients with Previously Resected Colon Polyps and First-Degree Female Relatives of Breast Cancer Patients1
Al B. Benson, III; Olufunmilayo I. Olopade; Mark J. Ratain; Alfred Rademaker; Sohrab Mobarhan; Lisa Stucky-Marshall; Suzanne French; M. Eileen Dolan
Phase III Randomized Study of Postradiotherapy Chemotherapy with α-Difluoromethylornithine-Procarbazine, N-(2-Chloroethyl)-N′-cyclohexyl-N-nitrosurea, Vincristine (DFMO-PCV) Versus PCV for Glioblastoma Multiforme1
Victor A. Levin; Joon H. Uhm; Kurt A. Jaeckle; Ali Choucair; Patrick J. Flynn; W. K. Alfred Yung; Michael D. Prados; Janet M. Bruner; Susan M. Chang; Athanassios P. Kyritsis; Mary Jo Gleason; Kenneth R. Hess
Molecular Oncology, Markers, Clinical Correlates
Loss of B7.2 (CD86) and Intracellular Adhesion Molecule 1 (CD54) Expression Is Associated with Decreased Tumor-infiltrating T Lymphocytes in Diffuse B-cell Large-cell Lymphoma1
Alison T. Stopeck; Andrea Gessner; Thomas P. Miller; Evan M. Hersh; Cynthia S. Johnson; Haiyan Cui; Yvette Frutiger; Thomas M. Grogan
Different Patterns of Allelic Loss (Loss of Heterozygosity) in Recurrent Human Pituitary Tumors Provide Evidence for Multiclonal Origins1
Richard N. Clayton; Marija Pfeifer; A. Brew Atkinson; Paul Belchetz; John A. H. Wass; Effie Kyrodimou; Mark Vanderpump; David Simpson; John Bicknell; William E. Farrell
High Frequency of Clonally Related Tumors in Cases of Multiple Synchronous Lung Cancers as Revealed by Molecular Diagnosis1
Shigeki Shimizu; Yasushi Yatabe; Takashi Koshikawa; Nobuhiro Haruki; Shunzo Hatooka; Masayuki Shinoda; Motokazu Suyama; Makoto Ogawa; Nobuyuki Hamajima; Ryuzo Ueda; Takashi Takahashi; Tetsuya Mitsudomi
The Evolution of Loss of Heterozygosity on Chromosome 17 during the Progression to Barrett’s Adenocarcinoma Involves a Unique Combination of Target Sites in Individual Specimens1
Julie R. Dunn; Julie Garde; Kevin Dolan; John R. Gosney; Beverly C. Oates; Alastair J. M. Watson; Patricia Fielding; John K. Field
Expression of Prostate-specific Membrane Antigen in Transitional Cell Carcinoma of the Bladder: Prognostic Value?1
Jean-Luc Gala; Sylvain Loric; Yves Guiot; Samuel Ray Denmeade; Alyssa Gady; Francis Brasseur; Michel Heusterspreute; Pascal Eschwège; Philippe De Nayer; Paul Van Cangh; Bertrand Tombal
Study of Dose Escalation and Sequence Switching of Administration of the Combination of Docetaxel and Doxorubicin in Advanced Breast Cancer
Kuniaki Itoh; Yasutsuna Sasaki; Hirofumi Fujii; Hironobu Minami; Tomoko Ohtsu; Hisashi Wakita; Tadahiko Igarashi; Yuko Watanabe; Yusuke Onozawa; Masaki Kashimura; Yasuo Ohashi
Analysis of Genetic Polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese Patients with Therapy-related Leukemia/Myelodysplastic Syndrome and de novo Acute Myeloid Leukemia1
Tomoki Naoe; Kunihiko Takeyama; Toshiya Yokozawa; Hitoshi Kiyoi; Masao Seto; Naokuni Uike; Teruo Ino; Atae Utsunomiya; Atsuo Maruta; Itsuro Jin-nai; Nanao Kamada; Yoshitsugu Kubota; Hiroyuki Nakamura; Chihiro Shimazaki; Shigeo Horiike; Yoshihisa Kodera; Hidehiko Saito; Ryuzo Ueda; Joseph Wiemels; Ryuzo Ohno
Experimental Therapeutics, Preclinical Pharmacology
Prostate Cancer Gene Therapy: Comparison of Adenovirus-mediated Expression of Interleukin 12 with Interleukin 12 plus B7-1 for in Situ Gene Therapy and Gene-modified, Cell-based Vaccines1
Gerald W. Hull; Mark A. McCurdy; Yasutomo Nasu; Chris H. Bangma; Guang Yang; Satoru Shimura; Hon-Man Lee; Jianxiang Wang; Justin Albani; Shin Ebara; Takefumi Sato; Terry L. Timme; Timothy C. Thompson
Antitumor Activity of Temozolomide Combined with Irinotecan Is Partly Independent of O6-Methylguanine-DNA Methyltransferase and Mismatch Repair Phenotypes in Xenograft Models1
Peter J. Houghton; Clinton F. Stewart; Pamela J. Cheshire; Lois B. Richmond; Mark N. Kirstein; Catherine A. Poquette; Ming Tan; Henry S. Friedman; Thomas P. Brent
Letters to the Editor
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.